1. Home
  2. CAPR vs INVZ Comparison

CAPR vs INVZ Comparison

Compare CAPR & INVZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • INVZ
  • Stock Information
  • Founded
  • CAPR 2005
  • INVZ 2016
  • Country
  • CAPR United States
  • INVZ Israel
  • Employees
  • CAPR N/A
  • INVZ N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • INVZ Auto Parts:O.E.M.
  • Sector
  • CAPR Health Care
  • INVZ Consumer Discretionary
  • Exchange
  • CAPR Nasdaq
  • INVZ Nasdaq
  • Market Cap
  • CAPR 324.6M
  • INVZ 369.4M
  • IPO Year
  • CAPR N/A
  • INVZ N/A
  • Fundamental
  • Price
  • CAPR $6.92
  • INVZ $1.95
  • Analyst Decision
  • CAPR Strong Buy
  • INVZ Strong Buy
  • Analyst Count
  • CAPR 6
  • INVZ 4
  • Target Price
  • CAPR $23.00
  • INVZ $3.27
  • AVG Volume (30 Days)
  • CAPR 1.1M
  • INVZ 8.7M
  • Earning Date
  • CAPR 11-11-2025
  • INVZ 11-12-2025
  • Dividend Yield
  • CAPR N/A
  • INVZ N/A
  • EPS Growth
  • CAPR N/A
  • INVZ N/A
  • EPS
  • CAPR N/A
  • INVZ N/A
  • Revenue
  • CAPR $13,392,150.00
  • INVZ $37,684,000.00
  • Revenue This Year
  • CAPR N/A
  • INVZ $153.22
  • Revenue Next Year
  • CAPR $7,894.07
  • INVZ $91.44
  • P/E Ratio
  • CAPR N/A
  • INVZ N/A
  • Revenue Growth
  • CAPR N/A
  • INVZ 17.32
  • 52 Week Low
  • CAPR $5.68
  • INVZ $0.45
  • 52 Week High
  • CAPR $22.90
  • INVZ $3.14
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 53.74
  • INVZ 45.14
  • Support Level
  • CAPR $6.05
  • INVZ $1.92
  • Resistance Level
  • CAPR $6.42
  • INVZ $2.11
  • Average True Range (ATR)
  • CAPR 0.39
  • INVZ 0.17
  • MACD
  • CAPR -0.01
  • INVZ -0.04
  • Stochastic Oscillator
  • CAPR 56.28
  • INVZ 4.84

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About INVZ Innoviz Technologies Ltd. Ordinary shares

Innoviz Technologies Ltd is a provider of solid-state LiDAR and perception solutions that feature technological breakthroughs across core components and bring enhanced vision and superior performance to enable safe autonomous driving at a mass scale. The company provides a complete and comprehensive solution for OEMs and Tier-1 partners that are developing and marketing autonomous driving vehicles to the passenger cars and other relevant markets, such as robotaxis, shuttles, delivery vehicles, buses and trucks and other industries that require 3-dimensional high resolution sensors. Company's solutions can enable safe autonomy for industries like logistics, drones, robotics, construction and other industrial applications, agriculture, smart city, smart infrastructure, security and mapping.

Share on Social Networks: